An interventional study of Scaling and Root Planing (SRP) in Periodontitis (Stage 3), sponsored by Saglik Bilimleri Universitesi. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Saglik Bilimleri Universitesi · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Periodontitis by Saglik Bilimleri Universitesi — 6 open to participants now, 7 under way, none of them phase 3. Periodontitis · Saglik Bilimleri Universitesi.
Among the 16 studies in Periodontitis by Saglik Bilimleri Universitesi, this one is one of 6 that started in 2026, is one of 7 with no phase, and was the 13th registered.
1,242 studies on the registry are indexed under Periodontitis; 304 are open to participants now.
Browse Periodontitis studies →6 of the 16 studies in Periodontitis by Saglik Bilimleri Universitesi are open now, in 1 country. Recruiting first, the newest first:
Saglik Bilimleri Universitesi · Sites in Turkey
Ages 18+ · Healthy volunteers
Saglik Bilimleri Universitesi · Sites in Turkey
Ages 18–65 · Healthy volunteers
Saglik Bilimleri Universitesi
Ages 18–40 · Women only · Healthy volunteers
Saglik Bilimleri Universitesi
Ages 18–60
Saglik Bilimleri Universitesi
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Of the 163 Periodontitis studies recruiting now, 80 (49%) set no upper age limit and 62 (38%) stop at 75 or younger; 12 take children under 18; 80 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 6 started in 2026.
This study's planned enrollment of 56 is above the median of 44 across 850 interventional studies indexed under Periodontitis.
Median enrollment 25 across the 7 interventional studies, 75 across the 9 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Saglik Bilimleri Universitesi is the lead sponsor of 458 studies on the registry; 124 are open to participants now.
4 of the studies in Periodontitis by Saglik Bilimleri Universitesi that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07146776Saglik Bilimleri UniversitesiTreatment of Intrabony Defects With Injectable Platelet-Rich Fibrin and Xenogenic Grafts | 2026-12-01 |
| NCT07475013Saglik Bilimleri UniversitesiEffects of Non-Surgical Periodontal Treatment on Inflammatory and Bone Markers in Periodontitis Patients | 2027-02-01 |
| NCT07699978Saglik Bilimleri UniversitesiMaternal Periodontal Inflammation and Pregnancy Outcomes: Salivary and Amniotic Biomarkers | 2027-03-15 |
| NCT07822269Saglik Bilimleri UniversitesiDental Loupe Versus Dental Operating Microscope for Non-Surgical Periodontal Treatment | 2027-08-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 16 studies in Periodontitis by Saglik Bilimleri Universitesi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to learn how a standard treatment called Scaling and Root Planing (SRP) affects specific biochemical markers in people with advanced gum disease (periodontitis). Periodontitis is a chronic condition that can lead to tooth loss.
The main focus is to investigate a marker called Glycoprotein Non-Metastatic B (GPNMB). This is the first study to examine GPNMB levels in both the serum and the gingival crevicular fluid of people with this condition. The study aims to answer these main questions:
How do GPNMB levels change after the Scaling and Root Planing treatment?
How does GPNMB relate to other markers that control bone health and healing, such as TGF-β1, RANKL, and Osteoprotegerin?
Researchers will compare 28 participants with advanced gum disease (Stage III Grade B/C) to 28 participants with healthy gums to see how these markers differ.
Participants in the gum disease group will:
Provide samples for laboratory analysis at the start of the study.
Receive the standard mechanical treatment of their teeth and roots (Scaling and Root Planing).
Return for follow-up visits 6 weeks and 3 months after treatment to provide new samples and have their gum health checked.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with Stage III Grade B/C periodontitis. At baseline, clinical periodontal measurements are recorded, and serum and gingival crevicular fluid samples are collected. All participants receive non-surgical periodontal therapy consisting of Scaling and Root Planing (SRP). Follow-up visits are conducted at 6 weeks and 3 months post-treatment for repeated clinical assessments and sample collection to evaluate changes in biochemical markers (GPNMB, TGF-β1, RANKL, and OPG).
Procedure: Scaling and Root Planing (SRP)
Periodontally healthy individuals. Participants undergo a single clinical periodontal examination and provide serum and gingival crevicular fluid samples at the baseline visit. This group serves as a reference for baseline biochemical marker levels. No therapeutic intervention is performed.
A standard non-surgical mechanical treatment that involves the removal of plaque and calculus from the teeth and root surfaces using ultrasonic devices and hand instruments.
Change in Gingival Crevicular Fluid (GCF) Glycoprotein Non-Metastatic B (GPNMB) Concentration
Concentration of GPNMB in gingival crevicular fluid samples measured by Enzyme-Linked Immunosorbent Assay (ELISA). Results will be expressed in picograms per microliter (pg/µL) to evaluate the local biochemical response following scaling and root planing (SRP).
Time frame: Baseline, 6 weeks, and 3 months post-treatment.
Change in Serum Glycoprotein Non-Metastatic B (GPNMB) Concentration
Concentration of GPNMB in serum samples measured by Enzyme-Linked Immunosorbent Assay (ELISA) to evaluate the systemic biochemical response. The results will be quantified and reported in picograms per milliliter (pg/mL) to evaluate the change in mean concentration values across the specified measurement intervals.
Time frame: Baseline, 6 weeks post-treatment, and 3 months post-treatment.
Change in Gingival Crevicular Fluid (GCF) Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) Concentration
Concentration of RANKL in gingival crevicular fluid samples measured via ELISA to assess local bone resorption activity. The data will be quantified in picograms per microliter (pg/µL) at baseline and post-treatment intervals.
Time frame: Baseline (before treatment), 6 weeks post-treatment, and 3 months post-treatment.
Change in Serum Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) Concentration
Concentration of RANKL in serum samples measured by ELISA to evaluate the systemic bone resorption activity. The results will be quantified and reported in picograms per milliliter (pg/mL) to evaluate the change in mean concentration values across the specified measurement intervals following periodontal therapy.
Time frame: Baseline (before treatment), 6 weeks post-treatment, and 3 months post-treatment.
Change in Gingival Crevicular Fluid (GCF) Osteoprotegerin (OPG) Concentration
Concentration of OPG in gingival crevicular fluid samples measured by ELISA to assess the local bone-protective response. The results will be quantified and reported in picograms per microliter (pg/µL) to evaluate the change in mean concentration values across the specified measurement intervals following scaling and root planing (SRP).
Time frame: Baseline (before treatment), 6 weeks post-treatment, and 3 months post-treatment.
Change in Serum Osteoprotegerin (OPG) Concentration
Concentration of OPG in serum samples measured by ELISA to evaluate the systemic bone-protective response. Measurement values will be reported in picograms per milliliter (pg/mL) to compare the changes in mean concentration values across the specified measurement intervals following periodontal therapy.
Time frame: Baseline (before treatment), 6 weeks post-treatment, and 3 months post-treatment.
Change in Gingival Crevicular Fluid (GCF) Transforming Growth Factor beta 1 (TGF-β1) Concentration
Concentration of TGF-β1 in gingival crevicular fluid samples measured by Enzyme-Linked Immunosorbent Assay (ELISA). This analysis evaluates the local anti-inflammatory response and tissue healing following scaling and root planing (SRP). The results will be quantified and reported in picograms per microliter (pg/µL) to evaluate the change in mean concentration values across the specified measurement intervals.
Time frame: Baseline (before treatment), 6 weeks post-treatment, and 3 months post-treatment.
Change in Serum Transforming Growth Factor beta 1 (TGF-β1) Concentration
Concentration of TGF-β1 in serum samples measured by ELISA to evaluate the systemic anti-inflammatory response. Measurement values will be reported in picograms per milliliter (pg/mL) to compare the changes before and after scaling and root planing (SRP).
Time frame: Baseline (before treatment), 6 weeks post-treatment, and 3 months post-treatment.
Change in Probing Pocket Depth (PPD)
Probing Pocket Depth (PPD) will be measured at six sites per tooth using a Williams periodontal probe to evaluate the depth of the periodontal pockets.
Time frame: Baseline (before treatment), 6 weeks post-treatment, and 3 months post-treatment.
Change in Clinical Attachment Loss (CAL)
Clinical Attachment Loss (CAL) will be measured at six sites per tooth using a Williams periodontal probe to assess the level of periodontal tissue attachment.
Time frame: Baseline (before treatment), 6 weeks post-treatment, and 3 months post-treatment.
Change in Plaque Index (PI)
Plaque Index (PI) will be used to assess the amount of plaque on the tooth surfaces to evaluate oral hygiene status.
Time frame: Baseline (before treatment), 6 weeks post-treatment, and 3 months post-treatment.
Change in Gingival Index (GI)
Gingival Index (GI) will be used to assess the severity of gingival inflammation based on color, consistency, and bleeding tendency.
Time frame: Baseline (before treatment), 6 weeks post-treatment, and 3 months post-treatment.
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Feb 2027, 10 months after the start.
Of 484 non-industry interventional studies with no phase under Periodontitis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 31. This study's planned 10 months is below that.
Counting every sponsor, half of 498 studies reached it within 15 months; a quarter within 8 and three quarters within 31.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Sep 2026 → Feb 2027 and completion Dec 2026 → Apr 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Saglik Bilimleri Universitesi →